These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30783375)

  • 1. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients.
    Luo H; Zhang XX; Cao LH; Tan N; Kang Q; Xi HL; Yu M; Xu XY
    World J Gastroenterol; 2019 Feb; 25(6):719-728. PubMed ID: 30783375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response.
    Lee HW; Kwon JC; Oh IS; Chang HY; Cha YJ; Choi IS; Kim HJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5348-56. PubMed ID: 26100697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Serum IFN- and IL-5 Levels in Response to Entecavir Therapy in Patients with Chronic Hepatitis B Virus Infection.
    Badary TM; ElBadawy O; Agban MN; Kamel S; Sadek A
    Egypt J Immunol; 2018 Jan; 25(1):93-103. PubMed ID: 30243001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience.
    Aljumah AA; Bin Selayem NA; Al-Howti SY; Dafallah M; AlGhamdi H; Mokhtar H; Albekairy AM; Sanai FM
    J Infect Chemother; 2019 Jan; 25(1):12-16. PubMed ID: 30366861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive role of early treatment dynamics of HBV RNA and HBcrAg for HBeAg seroconversion in children with chronic hepatitis B.
    Lai X; OuYang W; Li S; Qiu J; Zhang H; Jiang T; Qin X; Tang L; Gu Y; Yao Z; Peng S
    J Med Virol; 2024 May; 96(5):e29670. PubMed ID: 38773810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity.
    Li X; Li F; Zhang Y; Kang Y; Yu J; Yang F; Liu H; Qin Y; Huang Y; Mao R; Zhang J
    Biochem Biophys Res Commun; 2015 Sep; 464(4):1185-1191. PubMed ID: 26212437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
    Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
    Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
    Lee MH; Lee DM; Kim SS; Cheong JY; Cho SW
    J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
    J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
    Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy.
    Lin TC; Chiu YC; Chiu HC; Liu WC; Cheng PN; Chen CY; Chang TT; Wu IC
    World J Gastroenterol; 2018 Feb; 24(6):725-736. PubMed ID: 29456411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment.
    Guo R; Xie Y; Yang J; Lu H; Ye P; Jin L; Lin W
    Sci Rep; 2019 Apr; 9(1):5916. PubMed ID: 30976044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients.
    Zhang X; Lin SM; Ye F; Chen TY; Liu M; Chen YR; Zheng SQ; Zhao YR; Zhang SL
    J Viral Hepat; 2011 Jul; 18(7):e184-90. PubMed ID: 21692931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy.
    Ko SY; Choe WH; Kwon SY; Kim JH; Seo JW; Kim KH; Lee CH
    Scand J Gastroenterol; 2012 Nov; 47(11):1362-7. PubMed ID: 22934534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
    Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.